These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23357488)

  • 1. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.
    Velayos FS; Kahn JG; Sandborn WJ; Feagan BG
    Clin Gastroenterol Hepatol; 2013 Jun; 11(6):654-66. PubMed ID: 23357488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.
    Kaplan GG; Hur C; Korzenik J; Sands BE
    Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1509-20. PubMed ID: 17931345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
    Ananthakrishnan AN; Hur C; Juillerat P; Korzenik JR
    Am J Gastroenterol; 2011 Nov; 106(11):2009-17. PubMed ID: 21788991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
    Tang DH; Armstrong EP; Lee JK
    Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of infliximab for the treatment of Crohn's disease.
    Siegel CA; Hur C; Korzenik JR; Gazelle GS; Sands BE
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1017-24; quiz 976. PubMed ID: 16843733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.
    Ananthakrishnan AN; Korzenik JR; Hur C
    Inflamm Bowel Dis; 2013 Jan; 19(1):37-44. PubMed ID: 22416019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
    Vasudevan A; Ip F; Liew D; van Langenberg DR
    Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
    Bolin K; Hertervig E; Louis E
    J Crohns Colitis; 2019 Sep; 13(10):1323-1333. PubMed ID: 30893421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
    Wailoo AJ; Bansback N; Brennan A; Michaud K; Nixon RM; Wolfe F
    Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
    Dubinsky MC; Reyes E; Ofman J; Chiou CF; Wade S; Sandborn WJ
    Am J Gastroenterol; 2005 Oct; 100(10):2239-47. PubMed ID: 16181376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab in Crohn's disease: early and long-term treatment.
    Armuzzi A; De Pascalis B; Fedeli P; De Vincentis F; Gasbarrini A
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S271-9. PubMed ID: 18599000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
    J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of tumor necrosis factor in Crohn's disease].
    Rudakova AV
    Eksp Klin Gastroenterol; 2012; (5):83-6. PubMed ID: 23402177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.